BEIJING (Reuters) – A shortage of lab monkeys and a focus on developing a COVID-19 treatment have prompted Shanghai Junshi Biosciences to push back clinical trials of some other drugs, an executive at U.S. drugmaker Eli Lilly’s Chinese partner said.

Junshi’s experimental COVID-19 antibody treatment, JS016, is in early to mid-stage trials in the United States and Eli Lilly plans to combine it with another candidate and apply for a U.S.…

This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.